Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report

Ann Hematol. 2020 Apr;99(4):897-898. doi: 10.1007/s00277-020-03948-0. Epub 2020 Feb 7.

Authors

Pierre-Edouard Debureaux¹, Anne Brignier², Juliette Soret-Dulphy³, Delphine Réa², David Michonneau^{4

5}, Régis Peffault de Latour⁴, Flore Sicre de Fontbrune⁴, Simona Pagliuca⁴, Nathalie Parquet², Henrique Pedro Prata⁴, Amira Marouf⁴, Aliénor Xhaard⁴, Jean-Jacques Kiladjian³, Gérard Socié^{4

5}, Marie Robin⁴

Affiliations

¹ Hematology and transplantation unit, Saint Louis Hospital, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France. pierre-edouard.debureaux@aphp.fr.
² Therapeutic Apheresis unit, Saint Louis Hospital, APHP, Paris, France.
³ Clinical Investigations Center, Saint Louis Hospital, APHP, Paris, France.
⁴ Hematology and transplantation unit, Saint Louis Hospital, APHP, 1 avenue Claude Vellefaux, 75010, Paris, France.
⁵ Université de Paris, INSERM U976, Paris, France.

PMID: 32030449
DOI: 10.1007/s00277-020-03948-0

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Humans
Male
Middle Aged
Plateletpheresis / methods*
Primary Myelofibrosis / complications
Primary Myelofibrosis / diagnostic imaging
Primary Myelofibrosis / therapy*
Splenectomy / adverse effects
Splenectomy / trends
Thrombocytosis / diagnostic imaging
Thrombocytosis / etiology
Thrombocytosis / therapy*

Substances

Antineoplastic Agents